Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hélène Salaun"'
Autor:
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, Anne Floquet, Jole Ventriglia, Hélène Salaun, Malak Moubarak, Romain Rivoirard, Laura Polastro, Laure Favier, Benoit You, Dominique Berton, Thibault de la Motte Rouge, Laura Mansi, Cyril Abdeddaim, Karine Prulhiere, Laurence Lancry Lecomte, Magali Provansal, Cécile Dalban, Isabelle Ray-Coquard
Publikováno v:
Gynecologic Oncology. 173:98-105
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c4cd0920525f68022c27f1fe88d6b88
https://doi.org/10.1016/j.ygyno.2023.04.002
https://doi.org/10.1016/j.ygyno.2023.04.002
Autor:
Hélène Salaun, Charlotte Proudhon, Chantal Bourrier, Ellen Heitzer, Laura Xuereb, Michael R. Speicher, Nolwen Guigal-Stephan, Jean-Yves Pierga, Brian Paul Lockhart, Jelena Belic
Publikováno v:
Cancers
Cancers, Vol 12, Iss 1481, p 1481 (2020)
Volume 12
Issue 6
Cancers, Vol 12, Iss 1481, p 1481 (2020)
Volume 12
Issue 6
Background: Focal amplification of fibroblast growth factor receptor 1 (FGFR1) defines a subgroup of breast cancers with poor prognosis and high risk of recurrence. We sought to demonstrate the potential of circulating cell-free DNA (cfDNA) analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a9efe83b4ac36ea964b5756c762566
Autor:
Hélène Salaün, Lounes Djerroudi, Laura Haik, Anne Schnitzler, Guillaume Bataillon, Gabrielle Deniziaut, Ivan Bièche, Anne Vincent‐Salomon, Marc Debled, Paul Cottu
Publikováno v:
The Journal of Pathology: Clinical Research, Vol 10, Iss 3, Pp n/a-n/a (2024)
Abstract Everolimus is widely used in patients with advanced ER‐positive, HER2‐negative breast cancer. We looked at alterations in the PIK3CA/AKT/mTOR pathway in a multicenter cohort as potential biomarkers of efficacy. Patients with advanced ER
Externí odkaz:
https://doaj.org/article/53c363172074422ebc516d2dfdc2dc90
Autor:
Hélène Salaün, Leanne de Koning, Mathilde Saint-Ghislain, Vincent Servois, Toulsie Ramtohul, Agathe Garcia, Alexandre Matet, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, Manuel Rodrigues
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in m
Externí odkaz:
https://doaj.org/article/5c6e7f0d0a0c4c08a409631e649387d8